CStone to present updated CS2009 phase 1/2 NSCLC data at ASCO 2026

• CStone Pharmaceuticals flagged updated Phase I/II results for trispecific antibody candidate CS2009 in non-small cell lung cancer for presentation at ASCO 2026.
• Poster sessions are scheduled for May 30, 2026 and May 31, 2026, covering first-line and later-line lung cancer cohorts plus extended Phase I follow-up in advanced solid tumors.
• Clinical update pointed to encouraging anti-tumor activity in first-line lung cancer, including patient groups that typically respond poorly to immunotherapy.
• Later-line lung cancer data were described as showing deep, durable responses in heavily pretreated patients, including those previously treated with immunotherapy.
• Development plan targets global registration, with Phase III multi-regional trials expected to start by year end following US IND clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260422-12114780), on April 22, 2026, and is solely responsible for the information contained therein.